Investigational New Drugs

, Volume 18, Issue 4, pp 331–342 | Cite as

The Tegafur-Based Dihydropyrimidine Dehydrogenase Inhibitory Fluoropyrimidines, UFT/Leucovorin (ORZEL and S-1: a Review of Their Clinical Development and Therapeutic Potential

  • Paulo M. Hoff
Article

Abstract

Protracted intravenous regimens of fluorouracil (5-FU) may besuperior and better tolerated than intravenous bolus dosing. Aneffective oral regimen would allow a protracted course of 5-FUwithout the need for central venous lines and the associatedincrease in complications. Approximately 85% of 5-FU is degradedby dihydropyrimidine dehydrogenase (DPD); inhibition of thisenzyme pathway can increase the amount of circulating 5-FU. Two oralfluoropyrimidines commonly referred to as DPD inhibitoryfluoropyrimidines, or DIFs, UFT® plus leucovorin(LV) and S-1 are reviewed herein. These agents represent anapproach to more convenient, less toxic 5-FU therapy. In twomulticenter, randomized, phase III trials in patients withadvanced colorectal cancer, UFT/LV produced equivalent activitycompared with intravenous 5-FU/LV but with significantly lessmajor toxicity. The predominant side effect of UFT, diarrhea, isgenerally self-limited and easily managed. Myelosuppression andhand-foot syndrome were rarely noted in the schedules used inthese trials. S-1 has demonstrated promising activity in phaseII trials conducted in patients with gastric, colorectal, breast,and head and neck cancers. Ongoing trials are defining the rolesof these agents in a variety of malignancies.

dihydropyrimidine dehydrogenase fluoropyrimidines leucovorin oral chemotherapy S-1 UFT 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Leichman CG, Fleming TR, Muggia FM, Tangen CM, Ardalan B, Doroshow JH, Meyers FJ, Holcombe RF, Weiss GR, Mangalik A: Phase II study of fluorouracil and its modulation in advanced colorectal cancer: a southwest oncology group study. J Clin Oncol 13: 1303–1311, 1995Google Scholar
  2. 2.
    Lokich JJ, Ahlgren JD, Gullo JJ, Philips JA, Fryer JG: A prospective randomized comparison of continuous infusion fluorouracil with a conventional bolus schedule in metastatic colorectal carcinoma: a mid-atlantic oncology program study. J Clin Oncol 7: 425–432, 1989Google Scholar
  3. 3.
    Meta-analysis Group in Cancer: Efficacy of intravenous continuous infusion of fluorouracil compared with bolus administration in advanced colorectal cancer. J Clin Oncol 16: 301–308, 1998Google Scholar
  4. 4.
    Petrelli N, Herrera L, Rustum Y, Burke P, Creaven P, Stulc J, Emrich U, Mittelman A: A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma. J Clin Oncol 5: 1559–1565, 1987Google Scholar
  5. 5.
    Blanke C, Kasimis B, Schein P, Capizzi R, Kurman M: Phase II study of trimetrexate, fluorouracil, and leucovorin for advanced colorectal cancer. J Clin Oncol 15: 915–920, 1997Google Scholar
  6. 6.
    Wadler S, Schwartz EL, Goldman M, Lyver A, Rader M, Zimmerman M, Itri L, Weinberg V, Wiernik PH: Fluorouracil and recombinant alfa-2a-interferon: an active regimen against advanced colorectal carcinoma. J Clin Oncol 7: 1769–1775, 1989Google Scholar
  7. 7.
    Poon MA, O'Connell MJ, Wieand HS, Krook JE, Gerstner JB, Tschetter LK, Levitt R, Kardinal CG, Mailliard JA: Biochemical modulation of fluorouracil with leucovorin confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer. J Clin Oncol 9: 1967–1972, 1991Google Scholar
  8. 8.
    O'Dwyer PJ, Patil AR, Walczak J, Weiner LM, Litwin S, Comis RL: Phase II study of biochemical modulation of fluorouracil by low-dose PALA in patients with colorectal cancer. J Clin Oncol 8: 1497–1503, 1990Google Scholar
  9. 9.
    Heggie GD, Sommadossi JP, Cross DS, Huster WJ, Diasio RB: Clinical pharmacokinetics of 5-fluorouracil and its metabolites in plasma, urine, and bile. Cancer Res 47: 2203–2206, 1987Google Scholar
  10. 10.
    Ota K, Taguchi T, Kimura K: Report on nationwide pooled data and cohort investigation in UFT phase II study. Cancer Chemother Pharmacol 22: 333–338, 1988Google Scholar
  11. 11.
    Shirasaka T, Shimamato Y, Ohshimo H, Yamaguchl M, Kato T, Yonekura K, Fukushima M: Development of a novel form of an oral 5-fluorouracil derivative (S-1) directed to the potentiation of the tumor selective cytotoxicity of 5-fluorouracil by two biochemical modulators. Anti-Cancer Drugs 7: 548–557, 1996Google Scholar
  12. 12.
    EI Sayed Y, Sadee W: Metabolic activation of ftorafur [R,S-1-(tetrahydro-2-furanyl)-5-fluorouracil]: the microsomal oxidative pathway. Blochem Pharmacol 31: 3006–3008, 1982Google Scholar
  13. 13.
    Rustum Y: Mechamism-based improvement in the therapeutic selectivity of 5-FU prodrug alone and under conditions of metabolic modulation. Oncology 54(Suppl 1): 7–11, 1997Google Scholar
  14. 14.
    Diasio R: The role of dihydropyrimidine dehydrogenase (DPD) modulation in 5-FU pharmacology. Oncology 12(Suppl 7): 23–27, 1998Google Scholar
  15. 15.
    Fujii S, Ikenaka K, Fukushima M, Shirasaka T: Effect of uracil and its derivatives on antitumor activity of 5-fluorouracil and 1-(2-tetrahydrofuryl)-5-fluorouracil. Gann 69: 763–772, 1978Google Scholar
  16. 16.
    Taguchi T: Clinical application of blochemical modulation in cancer chemotherapy-biochemical modulation for 5-FU. Oncology 54(Suppl 1): 12–18, 1997Google Scholar
  17. 17.
    Ichikura T, Tornimatsu S, Okusa Y, Yahara T, Uefuji K, Tamakuma S: Thymidylate synthase inhibition by an oral regimen consisting of tegafur-uracil (UFT) and low dose leucovorin for patients with gastric cancer. Cancer Chemother Pharmacol 38: 401–405, 1996Google Scholar
  18. 18.
    Pazdur R: Phase I and pharmacokinetic evaluations of UFT plus oral leucovorin. Oncology 11(Suppl 10): 35–39, 1997Google Scholar
  19. 19.
    Ho DH, Pazdur R, Covington W, Brown N, Huo YY, Lassere Y, Kunitani J: Comparison of 5-fluorouracil pharmacokineties in patients receiving continuous 5-fluorouracil and oral uracil plus N+-(2'-tetrahydrofuryl)-5-fluorouracil. Clin Cancer Res 4: 2085–2088, 1998Google Scholar
  20. 20.
    Nogué AM, Saigi GE: Protracted treatment with UFT and leucovorin by oral way. Oncologia (Spain) 15: 114–116, 1992Google Scholar
  21. 21.
    Pazdur R, Lassere Y, Diaz-Canton E, Bready B, Ho D: Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 14 day schedule. Invest New Drugs 15: 123–128, 1997Google Scholar
  22. 22.
    González-Barón M, Feliu J, Ordonez A, Colmenarejo A, Espinosa E, Zamora P, de la Gandara I, Jalon JI: Phase I study of UFT plus leucovorin in advanced colorectal cancer: a double modulation proposal. Anticancer Res 1993: 759–762, 1993Google Scholar
  23. 23.
    Meropol NJ, Rustum YM, Petrelli NJ, Rodriguez-Bigas M, Frank C, Ho DH, Kurowski M, Creaven. PJ: A phase I and pharmacokinetic study of oral uracil, ftorafur, and leucovorin in patients with advanced cancer. Cancer Chemother Pharmacol 37: 581–586, 1996Google Scholar
  24. 24.
    Pazdur R, Lassere Y, Diaz-Canton E, Ho DH: Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 28 day schedule. Cancer Invest 16: 145–151, 1998Google Scholar
  25. 25.
    Spicer D, Muggia F, Tulpule A, et al.: Phase I circadian dosing of daily oral uracil (U) plus 1-(tetrahydro-2-furanyl)-5-fluorouracil (FT) with leucovorin (LV) (Abstract). Proc Amer Assoc Cancer Res 10: 342, 1991Google Scholar
  26. 26.
    Priest D, Schmitz J, Bunni M, Stuart R: Pharmacokinetics of leucovorin metabolites in human plasma as a function of dose administered orally and intravenously. J Natl Cancer Inst 83: 1806–1812, 1991Google Scholar
  27. 27.
    González-Barón M, Feliu J, de la Gandara I, Espinosa E, Colmenarejo A, Martinez-Martinez B, Blanco E, Garcia-Giron C, Juarez F, Garrido P: Efficacy of oral togafur modulation by uracil and leucovorin in advanced colorectal cancer. A phase II study. Eur J Cancer 31A: 2215–2219, 1995Google Scholar
  28. 28.
    Sanchiz F, Milla A: Tegafur-uracil (UFT) plus folinic acid in advanced rectal cancer. Jpn J Clin Oncol 24: 322–326, 1994Google Scholar
  29. 29.
    Saltz LB, Leichman CG, Young CW, Muggia FM, Conti JA, Spiess T, Jeffers S, Leichman LP: A fixed-ratio combination of uracil and ftorafur (UFT) with low-dose leucovorin. An active oral regimen for advanced colorectal cancer. Cancer 75: 782–785, 1995Google Scholar
  30. 30.
    Pazdur R, Lassere Y, Rhodes V, Ajani JA, Sugamian SM, Patt YZ, Jorius DV Jr, Markowitz AB, Abbruzzese JL, Bready B: Phase II trial of uracil and tegafur plus oral leucovorin: an effective oral regimen in the treatment of metastatic colorectal carcinoma. J Clin Oncol 12: 2296–2300, 1994Google Scholar
  31. 31.
    Pazdur R, Patt Y, Ajani J, Bland G, Dumas P, Sonnichsen D, Ferreira I, Birhofer M: Phase II/pharmacology study of UFT (BMS-200604) and leucovorin in refractory colorectal cancer patients. (Abstract) Proc Am Soc Clin Oncol 16: 270a, 1997Google Scholar
  32. 32.
    Meropol N, Sonnichsen D, Birkhofer M, Ferreira I, Noel D: Bioavailabillty and phase II study of oral UFT plus leucovorin in patients with relapsed or refractory colorectal cancer. Cancer Chemother Pharmacol 43: 221–226, 1999Google Scholar
  33. 33.
    Aranda E, Antón-Torres A, Sastre J, Navarro M, Rivera F, Carrato A, Bretón JJ, Grávalos C, Aparicio J, Fernandez-Martos, C, Díaz-Rubio E: UFT plus leucovorin (LV) in advanced colorectal cancer (CCR), a Phase II trial. (Abstract) Proc Am Soc Clin Oncol 18: 245a, 1999Google Scholar
  34. 34.
    Nogué M, Segui MA, Saigi E, Batiste-Alentorn E, Arcusa A, Boleda M, Anton I: Protracted treatment with tegafur and low dose oral leucovorin in patients with advanced colorectal carcinoma. Cancer 83: 254–258, 1998Google Scholar
  35. 35.
    Feliu J, González-Barón M, Espinosa E, Garcia Giron C, de la Gandara I, Espinosa J, Colmenarejo A, Jalon JI, Fernandez Y, de Castro J: Uracil and tegafur modulated with leucovorin: an effective regimen with low toxicity for the treatment of colorectal carcinoma in the elderly. Cancer 79: 1884–1889, 1997Google Scholar
  36. 36.
    Abad A, Navarro M, Sastre J, Marcuello E, Aranda E, Gallén M, Fernandez C, Martin C: Phase II continuous UFT plus folinic acid in elderly patients with colorectal cancer. (Abstract) Proc Am Soc Clin Oncol 16: 280a, 1997Google Scholar
  37. 37.
    González-Barón M, Feliu J, de la Gandara I, Colmenarejo A, Jalon JI, Chacon JI, Blanco E, Juarez F, Zamora P, Espinosa E: Phase II trial of uracil/tegafur (UFT) and leucovorin (LV) in advanced colorectal canccr. (Abstract) Proc Annu Meet Am Soc Clin Oncol 13: 204, 1994Google Scholar
  38. 38.
    Pazdur R, Douillard J-Y, Skillings JR, Eisenberg PD, Davidson N, Harper P, Vincent MD, Lembersky BC, Benner SE: Multicenter phase III study of 5-fluorouracil (5-FU) or UFT in combination with leucovorin (LV) in patients with metastatic colorectal cancer. (Abstract) Proc Am Soc Clin Oncol 18: 263a, 1999Google Scholar
  39. 39.
    Carmichael J, Popiela T, Radstone D, Falk S, Fey M, Oza A, Skovsgaard T, Martin C: Randomized comparative study of ORZEL (oral uracil/tegafur (UFT) plus leucovorin (LV) versus parenteral 5-fluorouracil (5-FU) plus LV in patients with metastatic colorectal cancer. (Abstract) Proc Am Soc Clin Oncol 18: 264a, 1999Google Scholar
  40. 40.
    Espinosa E, González-Barón M, Feliu J, Espinosa J, Lomas M, Casado E, Ordóñez A, de Castro J, Jalón JI, Blanco E, Zamora P: UFT-leucovorin as adjuvant treatment for Dukes' B2-C colon cancer. (Abstract) Proc Am Soc Clin Oncol 17: 275a, 1998Google Scholar
  41. 41.
    Pazdur R: New agents for colorectal cancers: oral fluorinated pyrimidines and oxaliplatin. In: Perry MC (eds) American Society of Clinical Oncology Education Book, Alexandria, 1998, pp 300–310Google Scholar
  42. 42.
    Laurie JA, Moertel CG, Fleming TR, Wieand HS, Leigh JE, Rubin J, McCormack GW, Gerstner JB, Krook JE, Malliard J: Surgical adjuvant therapy of large bowel carcinoma: an evaluation of levamisole and the combination of levamisole and fluorouracil. J Clin Oncol 7: 1447–1456, 1989Google Scholar
  43. 43.
    Moertel CG, Fleming TR, Macdonald JS, Haller DG, Laurie JA, Tangen CM, Ungerleider JS, Emerson WA, Tormey DC, Glick JH: Fluorouracil plus levamisole as effective adjuvant therapy after resection of stage III colon carcinoma: a final report. Ann Intern Med 122: 321–326, 1995Google Scholar
  44. 44.
    International Multicentre Pooled Analysis of Colon Cancer Trials: Efficacy of adjuvant fluorouracil and folinic acid in colon cancer. Lancet 345: 939–944, 1995Google Scholar
  45. 45.
    O'Connell MJ, Mailliard JA, Kahn MJ, Macdonald JS, Haller DG, Mayer RJ, Wieand HS: Controlled trial of fluorouracil and low-dose leucovorin given for 6 months as postoperative adjuvant therapy for colon cancer. J Clin Oncol 15: 246–250, 1997Google Scholar
  46. 46.
    Haller DG, Catalano PJ, Macdonald JS, Mayer RJ: Fluorouracil (FU), leucovorin (LV) and levamisole (LEV) adjuvant therapy for colon cancer: five-year final report of Int-0089. (Abstract) Proc Am Soc Clin Oncol 17: 256a, 1998Google Scholar
  47. 47.
    Wolmark N, Bryant J, Hyams DM, Grem J, Smith R, Atkins J, Dimitrov N, Fisher B, Oishi R, Prager D, Fehrenbacher L, Romond E, Colangelo L: The relative efficacy of 5-FU + leucovorin (FU-LV) and 5-FU-LV + interferon alfa-2a (IFN) in patients with dukes b and c carcinoma of the colon: first report of NSABP C-05. (Abstract) Proc Am Soc Clin Oncol 17: 255a, 1998Google Scholar
  48. 48.
    Smith R, Wieand H, Mamounas E: UFT plus calcium folinate vs 5-FU plus calcium folinate in colon cancer. Oncology 13 (Suppl 3): 44–47, 1999Google Scholar
  49. 49.
    Grem JL: Fluoropyrimidines. In: Chabner BA, Longo DL (eds) Cancer Chemotherapy and Biotherapy. Lippincott-Raven, Philadelphia, 1996, pp 149–211Google Scholar
  50. 50.
    Minsky BD: Preoperative combined modality treatment for rectal cancer. Oncology 8: 53–58, 1994Google Scholar
  51. 51.
    O'Connell MJ, Martenson JA, Wieand HS, Krook JE, Macdonald JS, Haller DG, Mayer RJ, Gunderson LL, Rich TA: Improving adjuvant therapy for rectal cancer by combining protracted-infusion fluorouracil with radiation therapy after curative surgery. N Engl J Med 331: 502–507, 1994Google Scholar
  52. 52.
    Hoff PM, Brito R, Slaughter M, Matei C, Lassere Y, Janjan N, Skibber J, Randolph J, Benner S, Pazdur R: Preoperative UFT, oral leucovorin and radiotherapy for patients with resectable rectal carcinoma: an oral regimen with complete pathological responses. (Abstract) Proc Am Soc Clin Oncol 17: 223a, 1998Google Scholar
  53. 53.
    Brito R, Lassere Y, Hoff P, Royce M, Ravandi F, Zukowski T, Janjan N, Skibber J, Benner S, Pazdur R: Schedule effect on maximum tolerated dose of Orzel®(UFT plus leucovorin). (Abstract) Proc Am Soc Clin Oncol 18: 204a, 1999Google Scholar
  54. 54.
    Feliu J, Calvillo J, Escribano A, De Castro J, Espinosa E, Ordóñez A, Zamora P, García de Paredes ML, De las Heras, B, Jiménez A, González Barón M: Neoadjuvant therapy of rectal carcinoma with UFT-folinic acid (LV) plus radiotherapy (RT). (Abstract) Proc Am Soc Clin Oncol 18: 239a, 1999Google Scholar
  55. 55.
    Childs H, Spencer S, Raben D, Tincher S, Newsome J, Robert F: Phase I study of combined UFT plus leucovorin and radiation therapy for pancreatic cancer. (Abstract) Proc Am Soc Clin Oncol 18: 249a, 1999Google Scholar
  56. 56.
    Feliu J, González-Barón M, Espinosa E, de Castro J, Ordonez A, Zarnora P, Gomez Navarro J, Espinosa J, Vilches Y, de la Gandara I: Cisplatin and UFT modulated with leucovorin for the treatment of advanced non small cell lung cancer. Am J Clin Oncol 19: 121–124, 1996Google Scholar
  57. 57.
    Wada H, Hitomi S, Teramatsu T: Adjuvant chemotherapy after complete resection in non-small-cell lung cancer. J Clin Oncol 14: 1049–1054, 1996Google Scholar
  58. 58.
    Richardet E, Mickiewicz E, Lerzo G, Bonaniasa M, Fein L, Cóppola F, Elli A, Jovtis S, Pedraza C, Bruno M, Ventriglia M, Cuevas M, Bártoli M, Alvarez A, Suárez A: UFT + leucovorin in advanced breast cancer: preliminary results in heavily pretreated patients. (Abstract) Proc Am Soc Clin Oncol 18: 226a, 1999Google Scholar
  59. 59.
    Dickson N, Nicholson BP, Cohen A, Hande KR, Blanke C, Lamar R, Johnson DH: A phase I trial of UFT, leucovorin and paclitaxel as first or second line therapy in patients with metastatic breast cancer. (Abstract) Proc Am Soc Clin Oncol 18: 112a, 1999Google Scholar
  60. 60.
    Klaassen U, Lang S, Borquez D, Oberhoff C, Hilger R, Benner S, Chazard M, Harstrick A, Seeber S: Oral UFT/leucovorin in combination with paclitaxel in the second line treatment of patients with metastatic breast cancer: results of a phase I/II trial. (Abstract) Proc Am Soc Clin Oncol 18: 107a, 1999Google Scholar
  61. 61.
    Hortobagyi GN: Treatment of breast cancer. N Engl J Med 339: 974–984, 1998Google Scholar
  62. 62.
    Kim YH, Cheong SK, Lee JD, Park JS, Shin SW, Kim JS: Phase II trial of oral UFT and leucovorin in advanced gastric carcinoma. Am J Clin Oncol 19: 212–216, 1996Google Scholar
  63. 63.
    Feliu J, González-Barón M, Garcia-Girón C, Espinosa E, Garcia-Alfonso P, Belon J, Blanco E, Garrido P, Ordonez A, Gomez-Navarro J, Zamora P: Treatment of patients with advanced gastric carcinoma with the combination of etoposide plus oral tegafur modulated by uracil and leucovorin. Cancer 78: 211–216, 1996Google Scholar
  64. 64.
    Kim YH, Kim BS, Seo JH, Chol CW, Jeon HJ, Hytin JH, Kim JS: A Phase II study of epirubicin, cisplatin, UFT and leucovorin in advanced gastric carcinoma. (Abstract) Proc Am Soc Clin Oncol 18: 289a, 1999Google Scholar
  65. 65.
    Pro B, Ajani JA, Dabaja B, Hargraves K, Fairweather J: A phase I study of taxol, carboplatin, and UFT plus leucovorin in patients with advanced upper gastrointestinal carcinomas. (Abstract) Proc Am Soc Clin Oncol 18: 261a, 1999Google Scholar
  66. 66.
    Findlay M, Cunningham D, Norman A, Mansi J, Nicolson M, Hickish, T, Nicolson V, Nash A, Sacks N, Ford H: A phase II study in advanced gastro-esophageal cancer using epirubicin and cisplatin in combination with continuous infusion 5-fluorouracil (ECF). Ann Oncol 5: 609–616, 1994Google Scholar
  67. 67.
    Andreyev HJ, Norman AR, Cunningham D, Padhani AR, Hill AS, Ross PJ, Webb A: Squamous oesophageal cancer can be downstaged using protracted venous infusion of 5-fluorouracil with epirubicin and cisplatin (ECF). Eur J Cancer 31A: 2209–2214, 1995Google Scholar
  68. 68.
    Evans TR, Lofts FJ, Mansi JL, Glees JP, Dalgleish AG, Knight MJ: A phase II study of continuous-infusion 5-fluorouracil with cisplatin and epirubicin in inoperable pancreatic cancer. Br J Cancer 73: 1260–1264, 1996Google Scholar
  69. 69.
    Colevas AD, Gomolin H, Amrein P, Norris C, Costello R, Barton J, Read R, Benner S, Posner M: Oral uracil and ftorafur (UFTTM) plus leucovorin (ORZEL®) in advanced loco-regional or metastatic squamous cell carcinoma of the head and neck. (Abstract) Proc Am Soc Clin Oncol 18:404a, 1999Google Scholar
  70. 70.
    Jacobs C, Lyman G, Velez-Garcia E, Sridhar KS, Knight W, Hochster H, Goodnough LT, Mortimer JE, Einhorn LH, Schacter L: A phase III randomized study comparing cisplatin and fluorouracil as single agents and in combination for advanced squamous cell carcinoma of the head and neck. J Clin Oncol 10: 257–263, 1992Google Scholar
  71. 71.
    Shirasaka T, Shimamoto Y, Fukushinia M: Inhibition by oxonic aeid of gastrointestinal toxicity of 5-fluorouracil without loss of its antitumor activity in rats. Cancer Res 53: 4004–4009, 1993Google Scholar
  72. 72.
    Peters GJ, Van Groeningen CJ, Schomage JH, Gall HE, Noordhuis P, de Vries M, Van Kullenburg ABP, Hanauske A-R: Phase I clinical and pharmacokinetic study of S-1, an oral 5-fluorouracil-based antineoplastic agent. (Abstract) Proc Amer Soc Clin Oncol 16: 227, 1997Google Scholar
  73. 73.
    Hoff PM, Wenske CA, Medgyesy DC, Royce, ME, Brito R, Zukowski TH, Ravandi F, Kuritani J, Pazdur R: Phase I and pharmacokinetic (PK) study of the novel oral fluoropyrimidine S-1. (Abstract) Proc Am Soc Clin Oncol 18: 173a, 1999Google Scholar
  74. 74.
    Horikoshi N, Mitachl Y, Sakata Y, Sugimachl K, Taguchl T: S-1, new oral fluoropyrimidine, is very active in patients with advanced gastric cancer (early phase II study). (Abstract) Proc Am Soc Clin Oncol 15: 206, 1996Google Scholar
  75. 75.
    Sakata Y, Ohtsu A, Horikoshi N, Sugimachi K, Mitachi Y, Taguchi T: Late phase II study of novel oral fluoropyrimidine anticancer drug S-1 (1 M tegafur-0.4 M gimestat-1 M otastat potassium) in advanced gastric cancer patients. Eur J Cancer 34: 1715–1720, 1998Google Scholar
  76. 76.
    Kurihara M, Koizumi W, Hasegawa K, Nakano K: Late phase II study of S-1, a novel oral fluoropyrimidine derivative, in patients with advanced gastric cancer. (Abstract) Proc Am Soc Clin Oncol 17: 262a, 1998Google Scholar
  77. 77.
    Baba H, Ohtsu A, Sakata Y, Mitachi Y, Sugimachi K, Taguchi T: Late phase II study of S-1 in patients with advanced colorectal cancer in Japan. (Abstract) Proc Am Soc Clin Oncol 17: 277a, 1998Google Scholar
  78. 78.
    Taguchi T, Morimoto K, Horikoshi N, Takashima S, Toge T, Kimura M, Sano M, Aoyama H, Ota J, Noguchi S: An early phase II clinical study of S-1 in patients with breast cancer. S-1 cooperative study group. Gan to Kagaku 1Zyoho 25: 1035–1043, 1998Google Scholar
  79. 79.
    Inuyama Y, Kida A, Tsukuda M, Kolino N, Satake B: Early phase II study of S-1 in patients with advanced head and neck cancer. S-1 cooperative study group. Gan to Kagaku Ryoho 25: 1151–1158, 1998Google Scholar
  80. 80.
    MacDonald JS, Schein PS, Woolley PV, Smythe T, Ueno W, Hoth D, Smith F, Boiron M, Gisselbrecht C, Brunet R, Lagarde C: 5-fluorouracil, doxorubicin, and mitomycin combination chemotherapy for advanced gastric cancer. Ann Intern Med 93: 533–536, 1980Google Scholar
  81. 81.
    Gohmann JJ, MacDonald JS: Chemotherapy of gastric cancer. Cancer Invest 7: 39–52, 1980Google Scholar
  82. 82.
    Wilke H, Preusser P, Fink U, Achterrath W, Lenaz L, Stahl M, Schober C, Link H, Meyer HJ, Lucke B: High-dose folinic acid/etoposide/5-fluorouracil in advanced gastric cancer: a phase II study in elderly patients or patients with cardiac risk. Invest New Drugs 8: 65–70, 1990Google Scholar

Copyright information

© Kluwer Academic Publishers 2000

Authors and Affiliations

  • Paulo M. Hoff
    • 1
  1. 1.Department of Gastrointestinal Oncology and Digestive DiseasesThe University of Texas M.D. Anderson Cancer CenterHoustonUSA

Personalised recommendations